JAN 25, 2018 1:37 PM PST

Therapeutic Antibody Inactivates Allergic Response

WRITTEN BY: Kara Marker

A new technique for treating allergies is on the way, and a therapeutic antibody is responsible. From Aarhus University, researchers introduce a novel antibody capable of inhibiting histamine production and an allergic reaction.

Obstruction and inflammation of the bronchiole characteristic of asthma. Credit: Yale Rosen

The single-domain, ultra-stable antibody prevents IgE, a human antibody associated with the allergic response in the immune system, from attaching to two cell receptors (CD23, FceRI). Normally, high levels of IgE are produced in response to exposure to allergens like pollen or insect venom. IgE antibodies attach to effector immune cells and produce histamine, which is the key ingredient for an allergic response.

But the therapeutic antibody Aarhus University researchers used in their studies thwarts the activity of IgE, blocking the allergic response that begins in the immune system. Additionally, the antibody is capable of removing IgE molecules after binding CD23 and FceRI.

“It doesn't matter that the body produces millions of allergen-specific IgE molecules,” explained Aarhus University’s Edzard Spillner. “When we can remove the trigger, the allergic reaction and symptoms will not occur.”

Interestingly enough, the new antibody is effective despite being smaller than therapeutic antibodies currently used in pharmaceutical products for allergy relief. Plus, its chemical structure allows it to be inhaled or swallowed, while many antibody-based allergy treatments available need to be injected.

The interaction between the experimental antibody and IgE has been tested in the lab with blood cells from people allergic to pollen and venom. Researchers believe it is applicable to other allergens and asthma as well.

Spillner and others are hoping to use this discovery to develop more effective treatments for allergies of all kinds.

"We can now precisely map how the antibody prevents binding of IgE to its receptors,” said Nick Laursen. “This allows us to envision completely new strategies for engineering medicine of the future.”

Experts at the Asthma and Allergy Foundation of America estimate that nasal allergies alone impact more than 50 million people in the United States, and that number continues to increase.

Before an allergy treatment with the new antibody as its main ingredient can become available to the public, Spillner, Laursen, and the other researchers from Aarhus University will have to conduct many clinical trials to ensure its efficacy and safety.

The present study was published in the journal Nature Communications.

Source: Aarhus University

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
MAR 20, 2020
Neuroscience
MAR 20, 2020
The Little Things Matter: The Mental Impact of Social Distancing
Image: Metropolitian State University of Denver The COVID-19 pandemic has caused social interactions, resources, and mos ...
MAR 16, 2020
Drug Discovery & Development
MAR 16, 2020
Critical Interleukin Leads to Drug Discovery
The immune molecule interleukin-2 (IL-2) is a growth factor that stimulates the immune system to produce T-cells. Their ...
MAR 28, 2020
Drug Discovery & Development
MAR 28, 2020
The Antibody Test to See if You've Already Had the Coronavirus
Knowing whether you’ve had the virus or not may not just reduce your need to panic- but also better help epidemiol ...
APR 09, 2020
Drug Discovery & Development
APR 09, 2020
Does Hydroxychloroquine Really Work Against COVID-19?
Although US President Donald Trump is a strong supporter of antimalarial drug Hydroxychloroquine as a treatment for COVI ...
MAY 07, 2020
Immunology
MAY 07, 2020
New COVID-19 Vaccine Defends Monkeys Against Infection
Researchers from Beijing-based Sinovac Biotech have reported preliminary results of a study into the development of a va ...
MAY 19, 2020
Drug Discovery & Development
MAY 19, 2020
COVID-19 Vaccine On Track for Late 2020
Moderna, a biotechnology company based in Massachusetts, has released information on its vaccine against COVID-19 from i ...
Loading Comments...